Pfizer Inc - Company Snapshot & SWOT Analysis
Pfizer Inc. is a research-based, global biopharmaceutical company headquartered in New York City, with its research headquarters in Groton, their global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. Pfizer work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases on time.
Their revenues are derived from the sale of their products and, to a much lesser extent, from alliance agreements, under which they co-promote products discovered or developed by other companies or us. The majority of their revenues come from the manufacture and sale of biopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June 2, 1942
Pfizer's full-year 2018 revenues totaled $53.6 billion, an increase of $1.1 billion, or 2%, compared to full-year 2017, reflecting operational growth of $791 million, or 2%, and the favorable impact of foreign exchange of $310 million, or less than 1%.
According to Pfizer's 2019 financial guidance, company anticipates continued strong growth from key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi as well as the expected loss of exclusivity of Lyrica in the U.S. in June 2019.
Spanning over 29 pages and 10 exhibits, “Pfizer Inc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Pfizer Inc- Company Snapshot & SWOT Analysis Report
Their revenues are derived from the sale of their products and, to a much lesser extent, from alliance agreements, under which they co-promote products discovered or developed by other companies or us. The majority of their revenues come from the manufacture and sale of biopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June 2, 1942
Pfizer's full-year 2018 revenues totaled $53.6 billion, an increase of $1.1 billion, or 2%, compared to full-year 2017, reflecting operational growth of $791 million, or 2%, and the favorable impact of foreign exchange of $310 million, or less than 1%.
According to Pfizer's 2019 financial guidance, company anticipates continued strong growth from key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi as well as the expected loss of exclusivity of Lyrica in the U.S. in June 2019.
Spanning over 29 pages and 10 exhibits, “Pfizer Inc - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Pfizer Inc- Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Pfizer Inc including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Pfizer Inc- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Pfizer Inc.
3.1.1 Company Profile
3.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Pfizer Inc.: Financial Performance
3.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Pfizer Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
Scope of the Pfizer Inc- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Pfizer Inc.
3.1.1 Company Profile
3.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Pfizer Inc.: Financial Performance
3.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
3.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.1.4 Pfizer Inc.: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Pfizer Inc.
Exhibit 3.2 Contact information of Pfizer Inc.
Exhibit 3.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 3.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 3.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)
Exhibit 3.9 SWOT Analysis of Pfizer Inc.
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Pfizer Inc.
Exhibit 3.2 Contact information of Pfizer Inc.
Exhibit 3.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 3.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 3.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)
Exhibit 3.9 SWOT Analysis of Pfizer Inc.